Results 201 to 210 of about 170,034 (262)

CD44‐Targeting Hydroxyapatite Nanoparticles (HAP) Induce Mitochondrial Dysfunction‐Driven PANoptosis and Immunogenic Cell Death (ICD) via Ca Overload in Colorectal Cancer

Advanced Science, EarlyView.
ABSTRACT Colorectal cancer (CRC) remains therapeutically challenging due to high metastasis, recurrence, and immunotherapy resistance driven by tumor microenvironment‐mediated immune evasion. Immunogenic cell death (ICD) offers a promising strategy to reshape the immune microenvironment, yet existing ICD inducers suffer from poor targeting efficiency ...
Yao Xiao, Yuxuan Yang, Haosen Qiu, Jia Yang, Hao Liang, Zhaojun Jiang, Xiao Tong, Yongying Li, Qunfeng Huang, Jiaming Wu, Tian Lin, Jiang Yu, Min Liang   +12 more
wiley   +1 more source

New spirooxindole pyrrolidine/pyrrolizidine analogs: design, synthesis, and evaluation as an anticancer agent. [PDF]

RSC Adv
Nivetha N, Venkatesan J, Murugan D, Rangasamy L, Wu SP, Velmathi S.   +5 more
europepmc   +1 more source

A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance

Advanced Science, EarlyView.
A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang, Tao Huang, Yiming Hao, Gui‐Feng Huang, Yi‐Lang Yan, Xin Fang, Ying Chen, Xiao‐Long Wei, Wai‐Lun Man, Wen‐Xiu Ni   +9 more
wiley   +1 more source

Amplification of Endoplasmic Reticulum Stress via Inhibiting Lipid Droplet Formation to Enhance Chemodynamic Immunotherapy

Advanced Science, EarlyView.
An endoplasmic reticulum (ER)‐targeted chemodynamic nanoagent (TCBQ/iLD‐ER NPs) comprising •OH‐generating tetrachloro‐1,4‐benzoquinone (TCBQ) and lipid droplets (LDs) formation inhibitor (iLD) is developed for chemodynamic immunotherapy of tumors. After ingestion by cancer cells, TCBQ/iLD‐ER NPs preferentially accumulate in the ER and react with ER ...
Huilan Cai, Shaoru Zhuang, Yang Zhu, Rujiang Ao, Meili Yu, Tingting Cui, Jun Wang, Xuegang Niu, Hongwei Huang, Shanshan Peng, Yu He, Lisen Lin, Huanghao Yang   +12 more
wiley   +1 more source

Feasibility, Acceptability, and Potential Effects of a Digital Oral Anticancer Agent Intervention: Protocol for a Pilot Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Ahmed S, Maheu C, Gotlieb W, Batist G, Loiselle CG.   +4 more
europepmc   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

Gaining Insight into Mitochondrial Targeting: AUTAC-Biguanide as an Anticancer Agent. [PDF]

Molecules
Vatté J, Bourdeau V, Ferbeyre G, Schmitzer AR.   +3 more
europepmc   +1 more source

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

Black Mulberry (Morus nigra L.): A Review of Attributes as an Anticancer Agent to Encourage Pharmaceutical Development. [PDF]

Adv Pharmacol Pharm Sci
Ferraz APCR, Figueiredo PO, Yoshida NC.
europepmc   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source